TSHA Research and Charts

TSHA - Taysha Gene Therapies Inc Ordinary Shares (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-01-06)

Last 2.05	Change ⇑ +0.13 (+6.77%)	Volume 3,377,913
	Open 1.93	High 2.06	Low 1.87

8EMA (Daily) 1.90	40EMA (Daily) 2.07	50EMA (Daily) 2.09	STO (Daily) 32.982	MACD Hist (Daily) 0.015
8EMA (Weekly) 2.050	40EMA (Weekly) 2.20	50EMA (Weekly) 2.23	STO (Weekly) 34.811	MACD Hist (Weekly) -0.031


Company Profile
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.